A detailed history of Rhumbline Advisers transactions in Pfizer Inc stock. As of the latest transaction made, Rhumbline Advisers holds 9,958,127 shares of PFE stock, worth $273 Million. This represents 0.27% of its overall portfolio holdings.

Number of Shares
9,958,127
Previous 9,993,551 0.35%
Holding current value
$273 Million
Previous $277 Million 0.47%
% of portfolio
0.27%
Previous 0.27%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024

SELL
$25.26 - $29.6 $894,810 - $1.05 Million
-35,424 Reduced 0.35%
9,958,127 $279 Million
Q1 2024

May 09, 2024

SELL
$25.89 - $29.73 $7.83 Million - $8.99 Million
-302,286 Reduced 2.94%
9,993,551 $277 Million
Q4 2023

Feb 08, 2024

SELL
$26.13 - $33.94 $3.34 Million - $4.33 Million
-127,657 Reduced 1.22%
10,295,837 $296 Million
Q3 2023

Nov 09, 2023

BUY
$32.09 - $37.51 $3.74 Million - $4.37 Million
116,428 Added 1.13%
10,423,494 $346 Million
Q2 2023

Aug 08, 2023

BUY
$36.12 - $41.79 $5.55 Million - $6.42 Million
153,664 Added 1.51%
10,307,066 $378 Million
Q1 2023

May 11, 2023

BUY
$39.39 - $51.28 $15.4 Million - $20 Million
390,520 Added 4.0%
10,153,402 $414 Million
Q4 2022

Feb 14, 2023

BUY
$41.75 - $54.5 $15.8 Million - $20.6 Million
377,345 Added 4.02%
9,762,882 $500 Million
Q3 2022

Nov 10, 2022

BUY
$43.76 - $53.42 $5.27 Million - $6.43 Million
120,422 Added 1.3%
9,385,537 $411 Million
Q2 2022

Aug 11, 2022

BUY
$46.53 - $55.17 $23.7 Million - $28.1 Million
509,399 Added 5.82%
9,265,115 $486 Million
Q1 2022

May 12, 2022

BUY
$45.75 - $56.69 $6.78 Million - $8.4 Million
148,187 Added 1.72%
8,755,716 $453 Million
Q4 2021

Feb 10, 2022

BUY
$41.32 - $61.25 $1.43 Million - $2.13 Million
34,698 Added 0.4%
8,607,529 $508 Million
Q3 2021

Nov 12, 2021

BUY
$39.25 - $50.42 $7.42 Million - $9.53 Million
188,970 Added 2.25%
8,572,831 $369 Million
Q2 2021

Aug 05, 2021

SELL
$35.91 - $40.68 $21.8 Million - $24.7 Million
-608,030 Reduced 6.76%
8,383,861 $328 Million
Q1 2021

May 06, 2021

SELL
$33.49 - $37.77 $14.7 Million - $16.6 Million
-439,043 Reduced 4.66%
8,991,891 $326 Million
Q4 2020

Feb 10, 2021

BUY
$33.47 - $42.56 $1.66 Million - $2.11 Million
49,552 Added 0.53%
9,430,934 $347 Million
Q3 2020

Nov 12, 2020

BUY
$31.75 - $37.25 $2.89 Million - $3.39 Million
90,965 Added 0.98%
9,381,382 $344 Million
Q2 2020

Aug 13, 2020

BUY
$30.12 - $36.54 $13.8 Million - $16.8 Million
458,713 Added 5.19%
9,290,417 $304 Million
Q1 2020

May 06, 2020

BUY
$27.03 - $38.62 $1.5 Million - $2.15 Million
55,609 Added 0.63%
8,831,704 $288 Million
Q4 2019

Feb 05, 2020

BUY
$32.92 - $37.36 $260,298 - $295,405
7,907 Added 0.09%
8,776,095 $344 Million
Q3 2019

Oct 23, 2019

SELL
$32.49 - $42.13 $5.6 Million - $7.27 Million
-172,448 Reduced 1.93%
8,768,188 $315 Million
Q2 2019

Aug 14, 2019

SELL
$36.98 - $41.52 $10.3 Million - $11.6 Million
-278,970 Reduced 3.03%
8,940,636 $387 Million
Q1 2019

May 01, 2019

SELL
$37.5 - $41.2 $8.64 Million - $9.49 Million
-230,278 Reduced 2.44%
9,219,606 $392 Million
Q4 2018

Jan 31, 2019

BUY
$38.47 - $43.86 $4.37 Million - $4.98 Million
113,506 Added 1.22%
9,449,884 $412 Million
Q3 2018

Nov 07, 2018

SELL
$34.47 - $41.81 $5.28 Million - $6.4 Million
-153,124 Reduced 1.61%
9,336,378 $411 Million
Q2 2018

Aug 06, 2018

SELL
$32.98 - $35.16 $6.62 Million - $7.05 Million
-200,605 Reduced 2.07%
9,489,502 $344 Million
Q1 2018

May 02, 2018

SELL
$31.91 - $37.02 $1.63 Million - $1.89 Million
-50,995 Reduced 0.52%
9,690,107 $344 Million
Q4 2017

Feb 09, 2018

BUY
$33.26 - $35.29 $8.55 Million - $9.07 Million
256,949 Added 2.71%
9,741,102 $353 Million
Q3 2017

Nov 06, 2017

BUY
$31.0 - $34.15 $294 Million - $324 Million
9,484,153
9,484,153 $339 Million

Others Institutions Holding PFE

About PFIZER INC


  • Ticker PFE
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 5,612,349,952
  • Market Cap $154B
  • Description
  • Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under ...
More about PFE
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.